Citius Oncology (CTOR) Other Non-Current Assets (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Other Non-Current Assets data on file, last reported at $71.3 million in Q1 2026.

• On a quarterly basis, Other Non-Current Assets fell 2.89% year-over-year to $71.3 million in Q1 2026; TTM through Mar 2026 was $71.3 million, a 2.89% decrease from a year earlier, with the FY2025 full-year figure at $73.4 million, changed 0.0% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $71.3 million, down from $72.8 million in the prior quarter.
• Over the last five years, Other Non-Current Assets for CTOR reached as high as $73.4 million in Q3 2024 and fell as low as $40.0 million in Q3 2023.
• Historically, Other Non-Current Assets has averaged $68.9 million across 4 years, with a median of $73.4 million in 2024.
• Across the five-year window, Other Non-Current Assets surged 83.5% in 2024 and slipped 2.89% in 2026, its largest moves.
• Year by year, Other Non-Current Assets stood at $40.0 million in 2023, then jumped by 83.5% to $73.4 million in 2024, then declined by 0.78% to $72.8 million in 2025, then fell by 2.13% to $71.3 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Assets figures were $71.3 million in Q1 2026, $72.8 million in Q4 2025, and $73.4 million in Q3 2025.